Avid Bioservices Inc (CDMO)

[biopharm]

Avid Bioservices receives royalties milestones net sale monies etc etc from Merck...I mean Oncologie

So do the BOD have fiduciary duty to make sure Oncologie lives up to the contract?

Should patents persuade Oncologie from halting full advancement of PS Targeting ?

Maybe we can ask Bronislaw Pytowski now working with Oncologie in NY but why NY?

________

The puzzle pieces to Merck build...and collaboration with Oncologie or against the full advancement of PS Targeting is the question

I have already proven Oncologie Laura E Benjamin ties to Biothera Mark T Uhlik etc etc and to Merck Michael Chisamore etc but Daniel J Hicklin I believe is another link to this Merck + Biothera ...to Oncologie initiative

Interesting times


___________

Bronislaw Pytowski

Top co-authors (50)

Kari Alitalo

Daniel J Hicklin

Yan Wu

Larry Witte
Kadmon Corporation

Kris Persaud
ImClone Systems

____________

The Blockbuster Drug Cyramza May Not Be The Savior Eli Lilly Was Hoping For
Jul. 1, 2015 5:30 AMEli Lilly and Company (LLY)
Summary

Cyramza has received four FDA approvals creating a large base of potential customers.

Cyramza faces stiff competition.

Cyramza alone will not be able to return Eli Lilly to its recent value.
Introduction

When Cyramza was initially approved for the treatment of stomach cancer in April of 2014, investors had high hopes for the drug. Just over a year later, Cyramza has seemingly succeeded having received a total of four FDA approvals. As Eli Lilly (NYSE: LLY) currently faces patent expirations and possible revenue loss, I am hopeful for resurgence, but I am not convinced that Cyramza will facilitate its second coming.

_____

Bronislaw (Bronek) Pytowski
Senior Director, Non-clinical research at Oncologie, Inc.
New York, New York
Biotechnology 457

Summary
Biotechnology professional with a proven drug development record from inception to clinical trials. I strongly believe in the importance of industry - academia collaboration and I have dedicated much of my professional time to initiating and managing such endeavors.

Professional highlight: The development of the monoclonal antibody ramucirumab (Cyramza®) from the initial identification of the target molecule, flk1/KDR (VEGFR-2), to global approval as a therapeutic agent in gastric, lung and colorectal cancers.

Significantly contributed to development of therapeutic monoclonal antibodies that target oncogenic tumor signaling, tumor angiogenesis and lymphangiogenesis. Most recently, led efforts to combine anti-angiogenic therapy with blockade of immunological checkpoints.

• Led ImClone Systems/Eli Lilly project teams for 25 years
• Formed advanced high-content in vitro imaging and screening team
• Formed and directed a high content, quantitative fluorescent microscopy team
• Contributed to pharmacodynamic and predictive biomarker discovery
• Established extensive network of academic collaborators in support of the Lilly portfolio
• Co-authored 58 research articles, 3 review articles and 3 book chapters
• 15 invited oral presentations at international scientific conferences
• Co-inventor on four ImClone Systems and Eli Lilly patents

I left Eli Lilly in in good standing in December 2017 by accepting a Voluntary Early Retirement offer. I am excited to continue contributing to drug development, once again in a small biotech company.

Experience
Image for Senior Director, Non-clinical research
Senior Director, Non-clinical research
Oncologie, Inc.
2018 – Present 1 year
Image for Senior Research Advisor
Senior Research Advisor
Eli Lilly and Company
January 2008 – December 2017 10 years
My principle role at Eli Lilly was that of non-clinical lead on the ramucirumab (Cyramza®) team. In this role, I directed non-clinical studies in support of the development of this monoclonal antibody as an anti-angiogenic agent for treatment of patients with solid tumors. My group:

• Developed in vitro assays for characterization of ramucirumab and several bi-specific antibodies containing a ramucirumab arm
• Developed in vivo strategies for modeling of combinatorial use of ramucirumab with standard-of-care chemotherapeutics, Lilly investigational molecules and immune checkpoint inhibitors
• Co-led in vivo studies in support of use of ramucirumab in in combination with immunological checkpoint inhibitors. Provided crucial mechanistic basis for the efficacy of this combination
• Explored potential biomarkers for anti-angiogenic therapy using animal models, patient plasma samples and patient tumor biopsies

I also established, managed, and coordinated an extensive network of academic collaborators in support of the Lilly portfolio of antibodies to VEGF family of receptors. I wrote all non-clinical sections of new drug applications (NDAs) for ramucirumab and provided support to the clinical and commercial teams through global presentations at conferences and internal training meetings.

Beyond ramucirumab, I initiated and directed investigational work on the VEGF receptor 3 antibody IMC-3C5 through phase 1/1b clinical trials. I coordinated internal and collaborative efforts to propose areas of clinical utility for this asset. I also provided non-clinical support for the team that developed an antibody to human VEGF receptor 1 (icrucumab) through phase 2 clinical trials. I also formed and directed a high content, quantitative, multi-parameter fluorescent microscopy team that provided extensive immunohistochemical data of tissues from proof-of-mechanism murine tumor studies of various Lilly assets.
_____

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents

Article· Literature Review in Pharmacology [?] Therapeutics 164 · June 2016 with 28 Reads
DOI: 10.1016/j.pharmthera.2016.06.001

Beverly L Falcon

Sudhakar Chintharlapalli at Eli Lilly

Mark T Uhlik at Biothera

Bronislaw Pytowski

Abstract
Interaction of numerous signaling pathways in endothelial and mesangial cells results in exquisite control of the process of physiological angiogenesis, with a central role played by vascular endothelial growth factor receptor 2 (VEGFR-2) and its cognate ligands. However, deregulated angiogenesis participates in numerous pathological processes. Excessive activation of VEGFR-2 has been found to mediate tissue-damaging vascular changes as well as the induction of blood vessel expansion to support the growth of solid tumors. Consequently, therapeutic intervention aimed at inhibiting the VEGFR-2 pathway has become a mainstay of treatment in cancer and retinal diseases. In this review, we introduce the concepts of physiological and pathological angiogenesis, the crucial role played by the VEGFR-2 pathway in these processes, and the various inhibitors of its activity that have entered the clinical practice. We primarily focus on the development of ramucirumab, the antagonist monoclonal antibody (mAb) that inhibits VEGFR-2 and has recently been approved for use in patients with gastric, colorectal, and lung cancer. We examine in-depth the pre-clinical studies using DC101, the mAb to mouse VEGFR-2, which provided a conceptual foundation for the role of VEGFR-2 in physiological and pathological angiogenesis. Finally, we discuss further clinical development of ramucirumab and the future of targeting the VEGF pathway for the treatment of cancer.


https://www.google.com/amp/s/www.researchgate.net/scientific-contributions/38440419_Bronislaw_Pytowski/amp

______

Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal,[2][3] founder and former CEO of ImClone Systems, now fully merged into Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed.[4][5]

https://en.m.wikipedia.org/wiki/Kadmon_Corporation